159 results on '"Kolbinger, Frank"'
Search Results
2. Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab.
3. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies.
4. Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab
5. Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis
6. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody
7. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase 3 studies
8. Force-Mediated Kinetics of Single P-Selectin/Ligand Complexes Observed by Atomic Force Microscopy
9. Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
10. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients:Week 52 results from the STEPIn study
11. Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The ARROW study.
12. Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study
13. IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling
14. ESDR365 - Secukinumab normalizes skin transcriptomes to a never-lesional state in new-onset psoriasis patients more rapidly than in chronic patients
15. IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study
16. 50238 Molecular characterisation of hidradenitis suppurativa clinical clusters through serum proteomic profiling: Insights from the SUNSHINE and SUNRISE phase 3 trials
17. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
18. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis
19. Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
20. Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis
21. Secukinumab rapidly reduces markers of both keratinocyte proliferation and skin integrity in psoriasis: 1264
22. Secukinumab, a novel anti–IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays: 1320
23. 17731 Evolving resolution of clinical, cellular, and transcriptomic inflammatory markers during 1-year IL-17A inhibition by secukinumab
24. Experimental analysis of acute murine oral candidiasis after in vivo Anti-IL-17A/ IL-17F treatment and in knockout mice: 279
25. Automation for higher throughput in protein expression: visions, facts and fictions
26. Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling
27. T cell epitope mapping of secukinumab and ixekizumab in healthy donors
28. The carbohydrate-recognition domain of E-selectin is sufficient for ligand binding under both static and flow conditions
29. A CARD10-Dependent Tonic Signalosome Activates MALT1 Paracaspase and Regulates IL-17/TNF-α–Driven Keratinocyte Inflammation
30. Interleukin‐17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis
31. Systematic identification of regulatory proteins critical for T-cell activation
32. P-selectin glycoprotein ligand-1 supports rolling on E- and P-selectin in vivo
33. IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
34. Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive measurement by tape stripping
35. Novel microperfusion method confirms higher IL-17A and β-defensin-2 levels in psoriasis lesional skin compared to non-lesional skin
36. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays
37. Secukinumab treatment rapidly leads to positive proteomic and transcriptional changes in psoriatic skin
38. Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis
39. Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
40. Differential requirements of IL-17 family cytokines in host defense against oral candidiasis (CCR6P.272)
41. Systematic identification of regulatory proteins critical for T-cell activation
42. 279
43. CD47 fusion protein targets CD172a+ cells in Crohn’s disease and dampens the production of IL-1β and TNF
44. Effect of IL-17A blockade with secukinumab in autoimmune diseases
45. Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment
46. A semi-automated large-scale process for the production of recombinant tagged proteins in the Baculovirus expression system
47. Automated baculovirus titration assay based on viable cell growth monitoring using a colorimetric indicator
48. An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells
49. Rapid expression cloning of receptors using epitope‐tagged ligands and high‐speed cell sorting
50. Functional Cloning of Src-like Adapter Protein-2 (SLAP-2), a Novel Inhibitor of Antigen Receptor Signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.